Monoclonal Antibody Diagnostic Reagent Market Size & Share

The global monoclonal antibody diagnostic reagent market was valued US$ 7,654.06 million in 2021; it is estimated to grow at a CAGR of 13.5% from 2022 to 2028.

Monoclonal antibodies (mAb) are important diagnostic reagents that are being used in biomedical research; microbiological research; in the diagnosis of Hepatitis, AIDs, influenza, herpes simplex, chlamydia infections; and in the treatment of infections and cancer. The monoclonal antibodies being directed at single epitopes are highly specific, homogeneous, and can be produced in unlimited quantities. The hybridoma-derived or bacterially cloned monoclonal antibody technology has enabled the mass production of highly specific probes for antigenic sites, whether on hormones, enzymes, receptors, or microbial products. Major factors driving the growth of this market include the rising prevalence of cancer and other chronic diseases, presence of strong pipeline of drugs under trial, and extensive R&D efforts to develop novel therapies.

The report offers insights and in-depth analysis of the global monoclonal antibody diagnostic reagent market, emphasizing various parameters, including market trends, technological advancements, market dynamics, and competitive landscape analysis of global leading market players. It also includes the impact of the COVID-19 pandemic on the market across all regions.

The overall impact of the COVID-19 pandemic on the monoclonal antibody diagnostic reagent market was positive; hence, the market continues to gain traction and is expected to grow in the coming years. Celltrion Group has announced that the Korean Ministry of Food and Drug Safety (MFDS) has approved regdanvimab (CT-P59), a monoclonal antibody for the treatment of COVID-19 for the prolonged use in elderly patients aged 50 years and over, or with at least one underlying medical condition such as obesity, cardiovascular disease, chronic lung disease, diabetes, chronic kidney disease, chronic liver disease, and patients with immunosuppressive agents with mild symptoms of COVID-19, and adult patients with moderate symptoms of COVID-19. Further, monoclonal antibody therapy, which has been successfully used in other countries to treat COVID-19 patients with mild or moderate symptoms, has now been approved by the Drugs Controller General of India (DCGI) for use in India.

Customize This Report To Suit Your Requirement

You will get customization on any report - free of charge - including parts of this report, or country-level analysis, Excel Data pack, as well as avail great offers and discounts for start-ups & universities

Get FREE CUSTOMIZATION

Monoclonal Antibody Diagnostic Reagent Market: Strategic Insights

• Get Top Key Market Trends of this report.
  This FREE sample will include data analysis, ranging from market trends to estimates and forecasts.

Free Sample PDF

Geography-Based Insights

By geography, the global monoclonal antibody diagnostic reagent market is segmented into North America (the US, Canada, and Mexico), Europe (France, Germany, the UK, Spain, Russia, Italy, and the Rest of Europe), Asia Pacific (China, India, Japan, Australia, South Korea, Kazakhstan, and the Rest of APAC), the Middle East & Africa (Saudi Arabia, the UAE, South Africa, and the Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America).

Market Insights

Extensive R&D Efforts to Develop Novel Therapies

The numerous application of mAbs involves the prevention, diagnosis, and treatment of disease. The application of mAbs in diagnosis is the most advanced, particularly for tests performed on the body fluids such as urine and blood. Additionally, mAbs diagnostic application includes techniques such as ELISA, western blot, immunoblot blot, flow cytometry, immunohistochemistry, radioimmunology assay, and electron microscopy. Also, mAbs intended for diagnostic application can detect antigens and antibodies against viral and fungal diseases of livestock and parasitic diseases.

Further, mAbs are valued reagents intended for abundant applications due to its selectivity, high binding affinity, and immunogenicity/low toxicity; mAbs are best suited for clinical, environmental, and elemental research. The diagnostic applications of mAbs also include medical devices, vitro tests, and medical imaging

Moreover, the utility of mAbs expanded for understanding a range of diseases by contributing to developing new immunotherapy treatments. For example, cancer therapies benefitted from research with mAbs, most probably for the development of RituximAb, proving an effective treatment for many cancers. Also, many mAbs are now recognized by the US Food and Drug Administration (FDA) as safe for utilization in commercial therapeutics. Such factors mentioned above are expected to contribute to the monoclonal antibody diagnostic reagent market growth during the forecast period.

Monoclonal Antibody Diagnostic Reagent Market Regional Insights

The regional trends and factors influencing the Monoclonal Antibody Diagnostic Reagent Market throughout the forecast period have been thoroughly explained by the analysts at Insight Partners. This section also discusses Monoclonal Antibody Diagnostic Reagent Market segments and geography across North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America.

Monoclonal Antibody Diagnostic Reagent Market Report Scope

Monoclonal Antibody Diagnostic Reagent Market Players Density: Understanding Its Impact on Business Dynamics

The Monoclonal Antibody Diagnostic Reagent Market market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.

Market players density refers to the distribution of firms or companies operating within a particular market or industry. It indicates how many competitors (market players) are present in a given market space relative to its size or total market value.

Major Companies operating in the Monoclonal Antibody Diagnostic Reagent Market are:

1. BioGenex
2. Bio-Rad Laboratories, Inc.
3. Biocare Medical, LLC
4. Celltrion Healthcare Co., Ltd.
5. Creative Diagnostics

Disclaimer: The companies listed above are not ranked in any particular order.

Tests-Based Insights

Based on tests, the global monoclonal antibody diagnostic reagent market is segmented into double antigen sandwich chemiluminescence method, enzyme linked immunosorbent assay, recombinant immunoblot assay, and dot-immunogold filtration assay. In 2021, the enzyme-linked immunosorbent assay segment accounted for the largest market share, and it is anticipated to register the highest CAGR from 2022 to 2028.

Application-Based Insights

Based on application, the global monoclonal antibody diagnostic reagent market is segmented into hormones diagnosis, tumor monitoring, virus detection, and other application. The tumor monitoring segment held the largest market share in 2021, and it is expected to register the highest CAGR during the forecast period.

The global monoclonal antibody diagnostic reagent market players are adopting organic strategies, including product launch and expansion, to expand their footprint and product portfolio worldwide and meet the growing product demand. A few of the key players operating in the market are BioGenex; Bio-Rad Laboratories, Inc.; Biocare Medical, LLC; Celltrion Healthcare Co., Ltd.; Creative Diagnostics; GenWay Biotech; Thermo Fisher Scientific Inc.; ABclonal, Inc.; Apto-Gen; and Abcam plc.